Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.300
+0.110 (5.02%)
At close: Oct 20, 2026, 4:00 PM EDT
2.350
+0.050 (2.17%)
Pre-market: Oct 21, 2026, 4:00 AM EDT
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $81.00K in the quarter ending June 30, 2026, a decrease of -72.07%. This brings the company's total for the last twelve months to $409.00K, down -66.88% year-over-year. In the year 2025, Perspective Therapeutics had annual revenue of $884.00K, down -39.20%. That makes Perspective Therapeutics the 44,739th largest company in the world by revenue and 6,402nd in the United States.
Revenue (ttm)
$409.00K
Revenue Growth
-66.88%
P/S Ratio
641.93
Revenue / Employee
$2,464
Employees
166
Market Cap
262.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 884.00K | -570.00K | -39.20% |
| Dec 31, 2024 | 1.45M | 20.00K | 1.39% |
| Dec 31, 2023 | 1.43M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 10.05M | 373.00K | 3.85% |
| Jun 30, 2020 | 9.68M | 2.37M | 32.35% |
| Jun 30, 2019 | 7.31M | 1.39M | 23.48% |
| Jun 30, 2018 | 5.92M | 1.16M | 24.41% |
| Jun 30, 2017 | 4.76M | -8.00K | -0.17% |
| Jun 30, 2016 | 4.77M | 163.00K | 3.54% |
| Jun 30, 2015 | 4.61M | 386.84K | 9.17% |
| Jun 30, 2014 | 4.22M | -306.08K | -6.76% |
| Jun 30, 2013 | 4.53M | -545.86K | -10.76% |
| Jun 30, 2012 | 5.07M | -167.89K | -3.20% |
| Jun 30, 2011 | 5.24M | -47.11K | -0.89% |
| Jun 30, 2010 | 5.29M | -131.73K | -2.43% |
| Jun 30, 2009 | 5.42M | -1.74M | -24.32% |
| Jun 30, 2008 | 7.16M | 1.42M | 24.76% |
| Jun 30, 2007 | 5.74M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Treace Medical Concepts | 205.31M |
| InfuSystem Holdings | 143.34M |
| RxSight | 127.58M |
| Standard BioTools | 84.60M |
| Electromed | 73.78M |
| Mobia Medical | 45.28M |
| TriSalus Life Sciences | 45.08M |
| ClearPoint Neuro | 42.28M |
CATX News
- 13 days ago - Perspective Therapeutics granted Fast Track designation for PSV359 - TheFly
- 13 days ago - Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors - GlobeNewsWire
- 14 days ago - Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium - GlobeNewsWire
- 18 days ago - Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 - GlobeNewsWire
- 19 days ago - 3 ‘Strong Buy’ Stocks Under $10 to Watch in October for 100%+ Upside - TipRanks
- 4 weeks ago - Perspective Therapeutics initiated with an Outperform at William Blair - TheFly
- 4 weeks ago - Perspective Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 weeks ago - Perspective Therapeutics announces trial collaboration agreement with Merck - TheFly